These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3276360)

  • 21. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy.
    Atkinson K; Biggs J; Concannon A; Dodds A; Young S; Wilson F; Ashby M; Downs K
    Aust N Z J Med; 1991 Dec; 21(6):850-6. PubMed ID: 1818544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.
    Forman SJ; Blume KG; Krance RA; Miner PJ; Metter GE; Hill LR; O'Donnell MR; Nademanee AP; Snyder DS
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2605-7. PubMed ID: 3079090
    [No Abstract]   [Full Text] [Related]  

  • 24. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?
    Storb R; Leisenring W; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan KM; Witherspoon R; Pettinger M; Bensinger W; Buckner CD; Clift R; Flowers ME; Hansen JA; Pepe M; Chauncey T; Sanders J; Thomas ED
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):194-201. PubMed ID: 9360781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors affecting survival in allogeneic bone marrow transplantation.
    Vogler WR; Winton EF; Reynolds RC; Heffner LT; Gordon DS
    Am J Med Sci; 1989 May; 297(5):300-8. PubMed ID: 2655445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Graft-versus-host disease after marrow transplantation.
    Storb R
    Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Problems and strategies for bone marrow transplantation in acute leukemia and chronic myelogenous leukemia.
    Santos GW
    Cancer Detect Prev; 1988; 12(1-6):589-96. PubMed ID: 3052840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
    Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
    Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
    Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
    Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
    von Bueltzingsloewen A; Belanger R; Perreault C; Bonny Y; Roy DC; Lalonde Y; Boileau J; Kassis J; Lavallee R; Lacombe M
    Blood; 1993 Feb; 81(3):849-55. PubMed ID: 8427977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients.
    Ringdén O; Remberger M; Aschan J; Lungman P; Lönnqvist B; Markling L
    Transplantation; 1994 Oct; 58(8):887-91. PubMed ID: 7940731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months.
    Yee GC; McGuire TR; St Pierre BA; Self SG; Zager RA; Sullivan KM; Deeg HJ
    Bone Marrow Transplant; 1989 Nov; 4(6):691-4. PubMed ID: 2684309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia.
    Storb R; Martin P; Deeg HJ; Sanders JE; Pepe M; Singer J; Anasetti C; Stewart P; Appelbaum FR; Sullivan KM
    Blood; 1992 Jun; 79(11):3091-2. PubMed ID: 1586751
    [No Abstract]   [Full Text] [Related]  

  • 34. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.
    Biggs JC; Atkinson K; Gillett E; Downs K; Concannon A; Dodds A
    Transplant Proc; 1986 Apr; 18(2):253-5. PubMed ID: 3515659
    [No Abstract]   [Full Text] [Related]  

  • 35. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
    Wagner JL; Seidel K; Boeckh M; Storb R
    Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia.
    Sorror ML; Leisenring W; Deeg HJ; Martin PJ; Storb R
    Biol Blood Marrow Transplant; 2005 Oct; 11(10):814-5. PubMed ID: 16182182
    [No Abstract]   [Full Text] [Related]  

  • 37. Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates.
    Deeg HJ; Storb R; Appelbaum FR; Kennedy MS; Graham TC; Thomas ED
    Transplantation; 1984 Jan; 37(1):62-5. PubMed ID: 6364490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.
    Locatelli F; Zecca M; Rondelli R; Bonetti F; Dini G; Prete A; Messina C; Uderzo C; Ripaldi M; Porta F; Giorgiani G; Giraldi E; Pession A
    Blood; 2000 Mar; 95(5):1572-9. PubMed ID: 10688810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
    Chao NJ; Snyder DS; Jain M; Wong RM; Niland JC; Negrin RS; Long GD; Hu WW; Stockerl-Goldstein KE; Johnston LJ; Amylon MD; Tierney DK; O'Donnell MR; Nademanee AP; Parker P; Stein A; Molina A; Fung H; Kashyap A; Kohler S; Spielberger R; Krishnan A; Rodriguez R; Forman SJ; Bluzme KG
    Biol Blood Marrow Transplant; 2000; 6(3):254-61. PubMed ID: 10871150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
    Yau JC; LeMaistre CF; Zagars GK; Williams LA; Meneghetti CM; Luke DR; Dunphy FR; Spinolo JA; Jagannath S; Spitzer G
    Bone Marrow Transplant; 1990 Apr; 5(4):269-72. PubMed ID: 2337738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.